explore -WSS

explore

author：hotspot 2025-09-30 01:13:32 - browse：2592

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Supreme Court strikes down use of affirmative action
Next article： How one patient went off dialysis — and others can too

knowledge

WSS

Intercept Pharmaceuticals sells itself for less than $1 billion

FDA advisers vote against ALS treatment from BrainStorm

Medicaid, Medicare dual

Study: Adult vaccinations pay for themselves in societal benefits

FDA seeks to regulate lab

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Wikipedia

explore

focus

Tori Bowie and the unacceptable rates of Black maternal death

Intercept Pharmaceuticals sells itself for less than $1 billion

Medical records are filled with copy

Inequities make cancer less preventable for women: report

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Inequities make cancer less preventable for women: report

Hollywood unions extend contract negotiations for actors

Kaiser Permanente unions announce official strike date

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What nurses really want: sufficient staffing for patient care

entertainment

How to improve immunocompromised access to mAb treatments

Covid vaccines: Private market messier than government rollout

Medicare drug price negotiation program allowed for now

How the Dana

Software glitch causes Tandem insulin pump to shutdown, FDA warns

After gene therapy, two congenitally deaf children hear for the first time

entertainment

focus

knowledge

leisure time